Dijon

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Atopic dermatitis (eczema)1 trial
• Coronary artery disease1 trial
• Familial hypercholesterolaemia1 trial
• Hidradenitis suppurativa1 trial
• Lung cancer1 trial
• Melanoma1 trial
• Metastatic breast cancer1 trial
• Stroke1 trial

Phase

• Phase 22 trials
• Phase 32 trials
• Phase 2/31 trial

Status

• Active, not recruiting5 trials
• Recruiting1 trial
• Terminated1 trial

Lead sponsor

• Novartis Pharmaceuticals7 trials

Running trials

• Active, not recruiting

  Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT07220577· Phase 2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation

  NCT06444087· Novartis Pharmaceuticals· Source

• Recruiting

  Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

  NCT05948943· Phase 2/3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France

  NCT05697146· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

  NCT03040973· Phase 2· Novartis Pharmaceuticals· Source

Closed trials

• Terminated

  A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

  NCT02967692· Phase 3· Novartis Pharmaceuticals· Source